Sorted By Test Name - Mayo Medical Laboratories

FSTAC
91655
80327
STEM
hospitalization due to cardiovascular disease using a cutpoint of 35 ng/mL. In addition, mortality risk was
significantly higher in patients with ST2 >35 ng/mL.(4) The risk appears early and persists throughout the
follow-up period. Clinical risk categories are substantiated by results from several large chronic heart
failure studies: -Low risk: < or =35.0 ng/mL -High risk: >35.0 ng/mL (high risk) Results should be
interpreted in the context of the individual patient presentation. Elevated ST2 results indicate an increased
risk for adverse outcomes and signal the adverse remodeling and progression of disease. The reference
interval was derived from normal donors without a history of cardiovascular disease, stroke, diabetes,
renal disease, liver disease, or autoimmune diseases. The reference range is gender dependent; however, it
is the clinical cutpoint that is recognized as providing the most utility. Knowledge of ST2 results in a
heart failure patient may assist in cardiovascular risk stratification and lead to more aggressive
management. There are no specific ST2 inhibitors available at this time and heart failure patients with
elevated ST2 concentrations should be treated and monitored according to established guidelines.
Angiotensin receptor blockers (ARBs) and aldosterone antagonists are thought to be particularly effective.
Reference Values:
Males:
or =18 years: < or =52.0 ng/mL
Females:
or =18 years: < or =38.7 ng/mL
Clinical References: 1. Weintraub NL, Collins SP, Pang PS, et al: Acute heart failure syndromes:
emergency department presentation, treatment, and disposition: Current approaches and future aims: a
scientific statement from the American Heart Association. Circulation 2010;122:1975-1996 2. Kakkar R,
Lee R: The IL-33/ST2 Pathway: therapeutic target and novel biomarker. Nat Rev Drug Discov
2008;7:827-8403 3. Seki K, Sanada S, Kudinova AY, et al: Interleukin-33 prevents apoptosis and
improves survival after experimental myocardial infarction through ST2 signaling. Circ Heart Fail
2009;2(6):684-691 4. Whellan DJ, Oâ€Connor CM, Lee, KL, et al: HF-ACTION Trial Investigators.
Heart failure and a controlled trial investigating outcomes of exercise training (HF-ACTION): design and
rationale. Am Heart J 2007;153(2):201-221 5. Dieplinger B, Januzzi J, Steinmair M, et al: Analytical and
clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma -
The Presage ST2 Assay. Clin Chim Acta 2009;409:33-40
Stachybotrys Panel II
Reference Values:
Stachybotrys chartarum/atra IgE: